Item 2.02. Results of Operations and Financial Condition.

On January 10, 2022, AlloVir, Inc. (the "Company") posted the corporate presentation referred to in Item 7.01 of this Current Report on Form 8-K, which announced that its unaudited cash, cash equivalents and marketable securities totaled $248.1 million as of December 31, 2021.

Item 7.01. Regulation FD Disclosure.

The Company is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others beginning on January 10, 2022. The corporate presentation will also be available in the investor relations section of the Company's website at http://allovir.com.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          AlloVir, Inc. corporate presentation.

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses